Clinical Trial: IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309900) titled 'IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies' on Nov. 26.

Brief Summary: This is an investigator-initiated, single-arm, open-label clinical study. It employs a dose-escalation design to evaluate the safety, pharmacokinetics, and preliminary efficacy of IASO208 injection in relapsed/refractory B-cell malignancies.

Study Start Date: Dec. 15

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory B-cell Malignancies

Intervention: GENETIC: IASO208 injection

IASO208 injection is a third-generation, self-inactivated, replication-deficient Lentiviral Vector (LVV) gene therapy research drug.

Recrui...